Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer
PurposeImmunotherapy has become widely applied in non-small cell lung cancer (NSCLC) patients. However, the relatively low response rate of immunotherapy monotherapy restricts its application. Combination therapy improves the response rate and prolongs patient survival; however, adverse events (AEs)...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.938827/full |
| _version_ | 1811283391428952064 |
|---|---|
| author | Yahan Huang Yahan Huang Jiao Wang Yanting Hu Pikun Cao Gang Wang Hongchao Cai Meixiang Wang Xia Yang Zhigang Wei Zhigang Wei Xin Ye |
| author_facet | Yahan Huang Yahan Huang Jiao Wang Yanting Hu Pikun Cao Gang Wang Hongchao Cai Meixiang Wang Xia Yang Zhigang Wei Zhigang Wei Xin Ye |
| author_sort | Yahan Huang |
| collection | DOAJ |
| description | PurposeImmunotherapy has become widely applied in non-small cell lung cancer (NSCLC) patients. However, the relatively low response rate of immunotherapy monotherapy restricts its application. Combination therapy improves the response rate and prolongs patient survival; however, adverse events (AEs) associated with immunotherapies increase with combination therapy. Therefore, exploring combination regimens with equal efficacy and fewer AEs is urgently required. The aim of this study was to evaluate the efficacy and safety of microwave ablation (MWA) plus camrelizumab monotherapy or combination therapy in NSCLC.Materials and methodsPatients with pathologically confirmed, epidermal growth factor receptor/anaplastic lymphoma kinase-wild-type NSCLC were retrospectively enrolled in this study. Patients underwent MWA to the pulmonary lesions first, followed by camrelizumab monotherapy or combination therapy 5–7 days later. Camrelizumab was administered with the dose of 200 mg every 2 to 3 weeks. Treatment was continued until disease progression or intolerable toxicities. The technical success and technique efficacy of ablation, objective response rate (ORR), progression-free survival (PFS), overall survival (OS), complications of ablation, and AEs were recorded.ResultsFrom January 1, 2019 to December 31, 2021, a total of 77 patients underwent MWA and camrelizumab monotherapy or combination therapy. Technical success was achieved in all patients (100%), and the technique efficacy was 97.4%. The ORR was 29.9%. The PFS and OS were 11.8 months (95% confidence interval, 9.5–14.1) and not reached, respectively. Smoking history and response to camrelizumab were correlated with PFS, and response to camrelizumab was correlated with OS in both the univariate and multivariate analyses. No periprocedural deaths due to ablation were observed. Complications were observed in 33 patients (42.9%). Major complications included pneumothorax (18.2%), pleural effusion (11.7%), pneumonia (5.2%), bronchopleural fistula (2.6%), and hemoptysis (1.3%). Grade 3 or higher AEs of camrelizumab, including reactive capillary endothelial proliferation, fatigue, pneumonia, edema, and fever, were observed in 10.4%, 6.5%, 5.2%, 2.6%, and 2.6% of patients, respectively.ConclusionMWA combined with camrelizumab monotherapy or combination therapy is effective and safe for the treatment of NSCLC. |
| first_indexed | 2024-04-13T02:10:45Z |
| format | Article |
| id | doaj.art-b9d08cc98f3a4dc283cf08b6d9c59eb1 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T02:10:45Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-b9d08cc98f3a4dc283cf08b6d9c59eb12022-12-22T03:07:18ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-08-011210.3389/fonc.2022.938827938827Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancerYahan Huang0Yahan Huang1Jiao Wang2Yanting Hu3Pikun Cao4Gang Wang5Hongchao Cai6Meixiang Wang7Xia Yang8Zhigang Wei9Zhigang Wei10Xin Ye11Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, ChinaShandong First Medical University & Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, ChinaDepartment of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, ChinaDepartment of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, ChinaDepartment of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, ChinaDepartment of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, ChinaDepartment of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, ChinaDepartment of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, ChinaDepartment of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, ChinaCheeloo College of Medicine, Shandong University, Jinan, ChinaDepartment of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, ChinaPurposeImmunotherapy has become widely applied in non-small cell lung cancer (NSCLC) patients. However, the relatively low response rate of immunotherapy monotherapy restricts its application. Combination therapy improves the response rate and prolongs patient survival; however, adverse events (AEs) associated with immunotherapies increase with combination therapy. Therefore, exploring combination regimens with equal efficacy and fewer AEs is urgently required. The aim of this study was to evaluate the efficacy and safety of microwave ablation (MWA) plus camrelizumab monotherapy or combination therapy in NSCLC.Materials and methodsPatients with pathologically confirmed, epidermal growth factor receptor/anaplastic lymphoma kinase-wild-type NSCLC were retrospectively enrolled in this study. Patients underwent MWA to the pulmonary lesions first, followed by camrelizumab monotherapy or combination therapy 5–7 days later. Camrelizumab was administered with the dose of 200 mg every 2 to 3 weeks. Treatment was continued until disease progression or intolerable toxicities. The technical success and technique efficacy of ablation, objective response rate (ORR), progression-free survival (PFS), overall survival (OS), complications of ablation, and AEs were recorded.ResultsFrom January 1, 2019 to December 31, 2021, a total of 77 patients underwent MWA and camrelizumab monotherapy or combination therapy. Technical success was achieved in all patients (100%), and the technique efficacy was 97.4%. The ORR was 29.9%. The PFS and OS were 11.8 months (95% confidence interval, 9.5–14.1) and not reached, respectively. Smoking history and response to camrelizumab were correlated with PFS, and response to camrelizumab was correlated with OS in both the univariate and multivariate analyses. No periprocedural deaths due to ablation were observed. Complications were observed in 33 patients (42.9%). Major complications included pneumothorax (18.2%), pleural effusion (11.7%), pneumonia (5.2%), bronchopleural fistula (2.6%), and hemoptysis (1.3%). Grade 3 or higher AEs of camrelizumab, including reactive capillary endothelial proliferation, fatigue, pneumonia, edema, and fever, were observed in 10.4%, 6.5%, 5.2%, 2.6%, and 2.6% of patients, respectively.ConclusionMWA combined with camrelizumab monotherapy or combination therapy is effective and safe for the treatment of NSCLC.https://www.frontiersin.org/articles/10.3389/fonc.2022.938827/fullmicrowave ablationcamrelizumablung cancerprogression-free survivaloverall survivalobjective response rate |
| spellingShingle | Yahan Huang Yahan Huang Jiao Wang Yanting Hu Pikun Cao Gang Wang Hongchao Cai Meixiang Wang Xia Yang Zhigang Wei Zhigang Wei Xin Ye Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer Frontiers in Oncology microwave ablation camrelizumab lung cancer progression-free survival overall survival objective response rate |
| title | Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer |
| title_full | Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer |
| title_fullStr | Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer |
| title_full_unstemmed | Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer |
| title_short | Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer |
| title_sort | microwave ablation plus camrelizumab monotherapy or combination therapy in non small cell lung cancer |
| topic | microwave ablation camrelizumab lung cancer progression-free survival overall survival objective response rate |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.938827/full |
| work_keys_str_mv | AT yahanhuang microwaveablationpluscamrelizumabmonotherapyorcombinationtherapyinnonsmallcelllungcancer AT yahanhuang microwaveablationpluscamrelizumabmonotherapyorcombinationtherapyinnonsmallcelllungcancer AT jiaowang microwaveablationpluscamrelizumabmonotherapyorcombinationtherapyinnonsmallcelllungcancer AT yantinghu microwaveablationpluscamrelizumabmonotherapyorcombinationtherapyinnonsmallcelllungcancer AT pikuncao microwaveablationpluscamrelizumabmonotherapyorcombinationtherapyinnonsmallcelllungcancer AT gangwang microwaveablationpluscamrelizumabmonotherapyorcombinationtherapyinnonsmallcelllungcancer AT hongchaocai microwaveablationpluscamrelizumabmonotherapyorcombinationtherapyinnonsmallcelllungcancer AT meixiangwang microwaveablationpluscamrelizumabmonotherapyorcombinationtherapyinnonsmallcelllungcancer AT xiayang microwaveablationpluscamrelizumabmonotherapyorcombinationtherapyinnonsmallcelllungcancer AT zhigangwei microwaveablationpluscamrelizumabmonotherapyorcombinationtherapyinnonsmallcelllungcancer AT zhigangwei microwaveablationpluscamrelizumabmonotherapyorcombinationtherapyinnonsmallcelllungcancer AT xinye microwaveablationpluscamrelizumabmonotherapyorcombinationtherapyinnonsmallcelllungcancer |